Strathmore Capital Advisors’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$682K Sell
5,400
-113
-2% -$13.2K 0.18% 72
2026
Q1
$617K Buy
5,513
+66
+1% +$7.62K 0.17% 76
2025
Q4
$573K Sell
5,447
-128
-2% -$12K 0.19% 68
2025
Q3
$468K Sell
5,575
-256
-4% -$21.1K 0.19% 74
2025
Q2
$488K Buy
+5,831
New +$463K 0.22% 67

Other funds holding MRK

Strathmore Capital Advisors's MRK Position: Q2 2026 in Review

Strathmore Capital Advisors reduced its Merck (MRK) stake by 2% in Q2 2026, selling an estimated $13.2K and leaving 5,400 shares worth $682K. The position accounts for 0.18% of the portfolio, ranked #72.

Strathmore Capital Advisors first reported a position in MRK in Q2 2025 and has held it in 5 quarters since. 3,852 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Strathmore Capital Advisors held 5,400 shares of Merck worth $682K as of Q2 2026.
  • Strathmore Capital Advisors sold 113 Merck shares in Q2 2026, an estimated $13.2K.
  • Merck made up 0.18% of Strathmore Capital Advisors's portfolio in Q2 2026, its #72 holding.
  • Strathmore Capital Advisors first reported a position in Merck in Q2 2025 and has held it in 5 quarters since.
  • 3,852 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Strathmore Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.